Vectura Group PLC  

(Public, LON:VEC)   Watch this stock  
Find more results for VEC
145.00
-1.00 (-0.68%)
Mar 27 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 144.50 - 148.12
52 week 113.25 - 158.75
Open 145.00
Vol / Avg. 401,656.00/364,822.00
Mkt cap 584.61M*
P/E     -
Div/yield     -
EPS -0.02*
Shares 403.18M
Beta     -
Inst. own     -
*GBP
May 20, 2015
Full Year 2014 Vectura Group PLC Earnings Release - 8:00AM GMT+1 - Add to calendar
Mar 10, 2015
Vectura Group PLC at Barclays Healthcare Conference
Mar 9, 2015
Vectura Group PLC at ROTH Conference
Jan 15, 2015
Vectura Group PLC at JPMorgan Healthcare Conference (Q&A Session)
Jan 15, 2015
Vectura Group PLC at JPMorgan Healthcare Conference
  

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin -23.20% -6.30%
Operating margin -36.60% -16.99%
EBITD margin - 11.78%
Return on average assets -3.00% -0.99%
Return on average equity -4.04% -1.27%
Employees 215 -
CDP Score - 74 C

Address

One Prospect West
CHIPPENHAM, SN14 6FH
United Kingdom - Map
+44-1249-667700 (Phone)
+44-1249-667701 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Vectura Group plc is a respiratory product development company. The Company focuses on the development of pharmaceutical therapies for treating airways-related diseases. The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, some of which are licensed to pharmaceutical companies. The Company�s product portfolio includes Adept, a 4% icodextrin solution used in surgery to reduce post-surgical adhesions; Advate used to treat haemophilia A; Asmasal used for rapid relief of asthma symptoms; Extraneal, a peritoneal dialysis solution containing icodextrin; Asmabec used as preventative therapy for asthma; Seebri Breezhaler, a muscarinic antagonist; Ultibro Breezhaler, a dual bronchodilator, and AirfluSal Forspiro, an inhaled combination therapy (salmeterol/fluticasone) for asthma and COPD. The Company�s pipeline products include VR588, VR611, VR942, VR475, VR465, VR647, VR179, VR736, SB010, NVA237, QVA149, VR876, VR315, VR506, and VR632.

Officers and directors

Christopher Paul Blackwell Ph.D. Chief Executive, Executive Director
Age: 52
Andrew J. Oakley Group Chief Financial Officer, Executive Director, Company Secretary
Age: 52
Trevor Michael Phillips Ph.D. Chief Operating Officer, President - US Operations, Director
Age: 53
Gerard Scheuch Chief Scientific Officer
Age: 58
Roger Heerman Chief Commercial Officer
Age: 41
Karl D. Keegan Ph.D. Chief Corporate Development Officer
Age: 48
Bruno F. J. Angelici Non-Executive Chairman of the Board
Age: 67
John Robert Brown Ph.D., CBE Senior Independent Non-Executive Director
Age: 59
Susan Elizabeth Foden Ph.D. Non-Executive Independent Director
Age: 61
Neil William Warner Non-Executive Independent Director
Age: 61